CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Drugs.com New Drug Applications
Original article

BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1

NDA FilingEncaleretPositive
AI Analysis

Summary

BridgeBio Pharma submitted an NDA to the FDA for Encaleret, a treatment for individuals with ADH1, representing a regulatory milestone for the company's drug development pipeline.

Importance:7/10
Sentiment:
0.70
NDA submissionFDAgenetic diseaseEncaleret
Related Companies

Read the original article

Published by Drugs.com New Drug Applications on May 12, 2026 8:05 PM

Read Original